Shareholders didn't seem to be thrilled with Scryb Inc.'s (CSE:SCYB) recent earnings report, despite healthy profit numbers. Our analysis suggests they may be concerned about some underlying details.
Zooming In On Scryb's Earnings
As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.
Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth.
Scryb has an accrual ratio of 1.40 for the year to September 2025. As a general rule, that bodes poorly for future profitability. And indeed, during the period the company didn't produce any free cash flow whatsoever. Even though it reported a profit of CA$4.47m, a look at free cash flow indicates it actually burnt through CA$2.8m in the last year. We also note that Scryb's free cash flow was actually negative last year as well, so we could understand if shareholders were bothered by its outflow of CA$2.8m. However, that's not the end of the story. We can look at how unusual items in the profit and loss statement impacted its accrual ratio, as well as explore how dilution is impacting shareholders negatively. The good news for shareholders is that Scryb's accrual ratio was much better last year, so this year's poor reading might simply be a case of a short term mismatch between profit and FCF. Shareholders should look for improved cashflow relative to profit in the current year, if that is indeed the case.
See our latest analysis for Scryb
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Scryb.
To understand the value of a company's earnings growth, it is imperative to consider any dilution of shareholders' interests. In fact, Scryb increased the number of shares on issue by 46% over the last twelve months by issuing new shares. Therefore, each share now receives a smaller portion of profit. To talk about net income, without noticing earnings per share, is to be distracted by the big numbers while ignoring the smaller numbers that talk to per share value. Check out Scryb's historical EPS growth by clicking on this link.
A Look At The Impact Of Scryb's Dilution On Its Earnings Per Share (EPS)
Scryb was losing money three years ago. And even focusing only on the last twelve months, we don't have a meaningful growth rate because it made a loss a year ago, too. But mathematics aside, it is always good to see when a formerly unprofitable business come good (though we accept profit would have been higher if dilution had not been required). And so, you can see quite clearly that dilution is having a rather significant impact on shareholders.
In the long term, if Scryb's earnings per share can increase, then the share price should too. But on the other hand, we'd be far less excited to learn profit (but not EPS) was improving. For that reason, you could say that EPS is more important that net income in the long run, assuming the goal is to assess whether a company's share price might grow.
How Do Unusual Items Influence Profit?
As it happens, there are a few different things to consider when we look at Scryb's profit and the last one we'll mention is CA$10m gain booked as unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that Scryb's positive unusual items were quite significant relative to its profit in the year to September 2025. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.
Our Take On Scryb's Profit Performance
Scryb didn't back up its earnings with free cashflow, but this isn't too surprising given profits were inflated by unusual items. The dilution means the results are weaker when viewed from a per-share perspective. On reflection, the above-mentioned factors give us the strong impression that Scryb'sunderlying earnings power is not as good as it might seem, based on the statutory profit numbers. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. Case in point: We've spotted 4 warning signs for Scryb you should be aware of.
Our examination of Scryb has focussed on certain factors that can make its earnings look better than they are. And, on that basis, we are somewhat skeptical. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Valuation is complex, but we're here to simplify it.
Discover if NorthPalm Capital might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About CNSX:NP
NorthPalm Capital
A technology company, holds ownership in various businesses and technologies from the fields of digital health, cybersecurity, biotech, and artificial intelligence.
Moderate risk and slightly overvalued.
Market Insights
Weekly Picks

When GPS fails: this small cap is fixing a $54B drone problem

Why Amdocs is a high conviction Buy for me?
Why SBM Offshore’s €30 Share Price May Be Too Harsh On Its Backlog

One of China's Fastest-Growing Restaurant Chains Trades on Just 7x Earnings and an 8% Dividend
Recently Updated Narratives
Vistra's data centers + AI

Dr. Sulaiman Al Habib Medical worth it or not ?

7/8/26 — Oscar Health: Trading 95.4% below Fair Value with +2070.2% Upside Potential
Popular Narratives

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.
A wonderful business at reasonable price.
Amazon's high growth, high tech segments propel its profits, while traditional segments plod along
Trending Discussion


